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Treatment Options for Colorectal Liver Metastases
by Mark S. Roh, M.D.
Chief; Liver Tumor Sur;gery
Department of General Sur;gery
Colorectal cancer commonly
metastasizes to the liver. Liver
metastases are present in 25%
of patients at the time the primary tumor is diagnosed and
will ultimately occur in up to
two-thirds of the patients who
develop advanced colorectal
cancer. In 50% of patients
with metastatic colorectal canMark S. Roh
cer, the liver is the only site of
disease. The overall prognosis for patients with untreated
liver metastases is poor, with survival of 4-8 months.
Clearly, liver metastases are a frequent and lethal complication of cancer and require effective therapy. Here I would
like to review the current treatment options for patients
with colorectal liver metastases and also describe three new
and potentially more effective treatment methods that
are being developed at The University ofTexas M. D.
Anderson Cancer Center: hepatic resection, intra-arterial
chemotherapy, and chemoembolization.

Hepatic Resection
More than 140,000 cases of colorectal cancer are diagnosed each year in the United States, approximately
40,000 of whom will die of hepatic metastases. The only
treatment with any potential of cure is hepatic resection.
The study that best defined the potential ability of hepatic
resection to cure patients with colorectal liver metastases
was from the Registry of Hepatic Metastases. This registry
contains the records of 859 patients from 24 institutions
who have undergone hepatic resection for colorectal liver

metastases. In this study, overall 5-year survival was 33%.
This result was significant, considering that patients who
are not treated for colorectal liver metastases consistently
do not survive beyond 3 years.
At the M. D. Anderson Cancer Center, patients are considered for hepatic resection only if they are medically fit to
withstand major surgery, if disease is limited to the liver,
and if there are fewer than four metastases. If these three
criteria are fulfilled, then a more extensive preoperative
evaluation is performed, including an intravenous (IV)

contrast computed tomographic (CT) scan of the entire
abdomen and pelvis with a detailed examination of the
mesenteric, para-aortic, portal, and celiac lymphatics. Colonoscopy of the entire colon is performed if the primary
colon resection occurred more than 3 months previously.
Further x-ray evaluation is performed only for specific complaints. All patients undergo a celiac and superior mesenteric arteriogram to define hepatic arterial anatomy and
thus the vascular supply to the tumor. Because approxicontinued on page 2
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mately 40% of patients have anomalous hepatic arterial
anatomy, this knowledge is important in planning a
resection.
In addi_tion, all patients at M. D. Anderson undergo a
dynamic CTangiogram. This is a more sensitive test than
the IV-contrast CT scan because it can detect small (1-2 cm)
lesions and also define the relationship of the metastases to
the hepatic veins. The rationale for a CT angiogram is based
on the fact that metastases derive the majority (90-95%) of
their blood supply from the hepatic artery and a minimal
amount from the portal vein. Thus, contrast injection into
the portal vein will maximally enhance the normal liver
parenchyma, and the metastases will appear as low attenuation defects. If the preoperative evaluation fails to detect
extrahepatic disease and the metastases appear to be technically resectable, the patient undergoes an exploratory laparotomy and possibly a hepatic resection.
At surgery, the abdomen is explored in detail. The lymphatics (celiac, portal, para-aortic, and mesenteric), anastomotic site, and peritoneal surfaces are closely examined for
metastatic disease. If no disease is discovered, the liver is
examined with intraoperative ultrasound. We use a T-shaped
probe with a 5- or 7. 5-mHz frequency. The three-step
examination begins with identification of the hepatic
veins and follows their course throughout the liver. The
second step traces the portal pedicles (consisting of the
portal vein, hepatic artery, and bile duct) throughout the
liver. The final step is a careful examination of the hepatic
parenchyma, which can determine if additional lesions are
present, define tumor/vessel relation, and aid in planning
the resection.
Many types of hepatic resections can be performed and
are classified as either anatomic or segmental (nonanatomic).
The type of resection is determined by the size and anatomic location of the metastases. Large lesions ( > 5 cm)
that are confined to one anatomic lobe or metastases that
are located adjacent to important vascular structures
require an anatomic resection. Examples of anatomic resection are a right or left lobectomy and a trisegmentectomy
(resection of the entire right lobe and medial segment of
the left).
Not every patient requires a hepatic lobectomy to completely extirpate the metastatic disease. A proportion of
patients can potentially be cured by a limited hepatic resection or segmentectomy. We prefer to perform a segmentectomy, since this procedure significantly reduces blood loss,
shortens operating time, lowers morbidity and mortality,
and achieves long-term survival. Segmentectomy should
be performed only if tumor size is less than 4 cm and if a
tumor-free surgical margin greater than 1 cm can be
achieved. The anatomic rationale for this procedure is
based on the eight functional units that compose the liver,
each of which possesses a separate and identifiable portal
pedicle and draining hepatic vein. The use of intraoperative
ultrasound is mandatory to identify the intrahepatic vascu-

lar structures. This procedure can be safely performed in
three isolated hepatic segments that will permit resection of
bilobar metastases. Resection ofbilobar metastases should
be considered, since the disease-free survival has been
shown to be equivalent to that of patients who undergo
resection of the same number of unilobar metastases.

Intra-arterial Chemotherapy
Unfortunately, only 10-15% of patients with colorectal
liver metastases have resectable disease. O ne treatment
option for the remaining patients is hepatic arterial chemotherapy; Metastases derive 90-95% of their blood supply
from the hepatic artery, and the normal liver derives 75%
of the blood supply from the portal vein . The rationale
behind this treatment, then, is that intra-arterial chemotherapy will achieve a higher concentration in the tumor
than in the normal liver. At M . D. Anderson the majority
of patients receive intra-arterial t herapy t hrough a surgically implantable pump that continuously infuses drugs
and permits the patient to perform normal daily activities
while receiving therapy. The pump is placed in a subcutaneous pocket and attached to a catheter t hat is placed in the
hepatic artery. Objective tumor response to floxuridine

(FUDR) administration has been shown to be significantly
better in patients receiving intra-arterial therapy (42%)
than in those receiving IV therapy (10%). The toxicity of
intra-arterial therapy is primarily hepatobiliary and manifested initially by elevated liver enzymes . If therapy is
continued despite abnormal liver function, permanent
hepatocellular drainage can occur (i. e ., biliary sclerosis).
Although intra-arterial therapy improves response, significant survival benefit has not yet been demonstrated. At
M. D. Anderson ongoing protocols are trying to improve
efficacy of intra-arterial therapy and achieve prolonged survival. One study is examining the effect ofintra-arterial
FUDRand folinic acid in the treatment ofliver metastases.
Potentially, the addition of folinic acid will enhance
FUDR's effectiveness and improve response. In addition,
continued on page 8
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Early Discharge for Mastectomy Patients
Does Not Increase Morbidity
Will cost containment diminish the quality of patient
care? To some, these goals are constantly at odds, but
Michael J. Edwards, M.D., thinks otherwise. Edwards and
four colleagues at The University ofTexas M. D. Anderson
Cancer Center compared two groups of mastectomy
patients: one before a policy of early discharge was implemented, and one after. .For the latter, they found that
charges were reduced by 39% and length of hospitalization
was reduced by 6 days with no increase in morbidity.
Edwards bases his confidence in cost containment on the
success of his study. "But the ' cost-effective' measures
imposed on physicians by insurance carriers may not all be
as valid," said Edwards, a fellow in the Division of Surgery.
" It's important, therefore, that physicians gather hard data
to confirm that the care provided is not only cost effective
but safe. "
Edwards was the principal investigator in a study (published last fall in the Annals ofSur;gery, 208: 330-336, 1988)
t hat examined one such cost-containment policy: early discharge for mastectomy patients. Edwards and colleagues
compared 59 patients who had mastectomies in 1983-84
with 61 pa,tients who had mastectomies in 1986-87. The
first group had "standard management": patients were
admitted 24 hours before surgery and were discharged only
after surgical drains had been removed. Patients in the second group, however, were admitted on the day of surgery
and discharged " early" with drains in place. The 6-day
reduction of the length of stay (from 10.5 days in the first
group to 4. 3 in the second) resulted in an average savings
of $1,886 per patient (adjusted for a 12% increase in inflation). But more important, complication rates (seroma,
hematoma, wound necrosis, and infection) between the
two groups were not statistically different.

patient populations from a number of hospitals. These
variables have to be taken into account when interpreting
the data. In our study, all operations were done by the
same surgeon, with the same technique, same drains, and
same equipment. The only things that changed between
the historical control group and the second group were
when patients were admitted and when they went home."
Edwards said the goal was to discharge the patient by the
third or fourth postoperative day. Patients were discharged
only if they had begun eating, were ambulatory, had adequate pain control, and had no special nursing requirements. Patients also had to be familiar with proper wound
and drain care procedures. "Patient education was very
important, and it began in the outpatient clinic at the time
surgery was first proposed," Edwards said. "The patient
was taught how to manage the wound and drainage catheters before she was admitted to the hospital and also while
recuperating after surgery. By her last day in the hospital,
the patient was given complete responsibility for drain care
under the supervision of the nursing staff."
If the patient had underlying chronic disease or needed
but lacked a care partner at home, then she remained hospitalized as long as necessary. Consequently, 15 of the 61
patients (25%) treated in 1986-87 required longer hospitalizations for these reasons.
"Clearly this policy does not apply to all patients,"
Edwards said. "But at an institution like M. D. Anderson
that performs 400 mastectomies a year, hospital charges
could potentially be reduced by $750,000. And I think it's
safe to say, based on this experience, that patients prefer
being at home. Some patients in this study lived alone and
did not need a care partner to assist them, so the type of
self-care required is not extensive.''
Since the conclusion of the study, hospitalization for
mastectomy patients has been reduced further, to 3.2 days.
Because of this success a majority of the physicians in the
Department of Surgery have adopted this policy. Moreover, this policy is being extended to patients with other
types of operations, such as regional lymphadenectomies .
"Patients having plastic surgery or surgery for extremity
sarcomas can also be discharged with catheters in place,"
Edwards said.

Unique Study
Admission on the same day of surgery and early discharge
have been increasingly practiced, particularly by hospitals
in the northeast and California, Edwards said. Though
numerous studies have been published regarding the safety
of these policies, this study was unique in that "confounding" variables were kept to a minimum.
''This study is important,'' Edwards said, ''because it
was the first to examine two groups of patients who were
operated on by the same surgeon (Frederick C. Ames,
M.D., Department of General Surgery). Some studies
compared patients operated on by different surgeons using
a variety of techniques, whereas others compared different

Physicians Must Be Involved
Though early discharge cannot be applied to all patients,
the potential reduction in cost is still significantcontinued on page 7
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Improved Treatments for Non-Hodgkin's Lymphoma
by Lillian M. Fuller, M.D.
Annie Laurie Howard Professor ofRadiotherapy
and Deputy Chairman
Department ofClinical Radiotherapy

Patients with diffuse large cell lymphoma and particularly
those with disease in the oral pharynx may need prompt
attention. Beginning with the follicular lymphomas, we
will discuss investigative procedures, approaches to
treatment, and results.

Non-Hodgkin's lymphomas
occur in both adults and children. However, the relative
incidence of these diseases differs between populations.
Based on correlations of
prognosis with histologic
features, these diseases have
been categorized according
to the Working Formulation
Lillian M. Fuller
Classification as low, intermediate, and high grade. In children, the high-grade
lymphomas predominate, whereas most adults have lowor intermediate-grade disease.
In general, chemotherapy is the undisputed primary
treatment for intermediate- and high-grade lymphomas and
low-grade disease in the late stages. Though radiotherapy's
role has yet to be firmly delineated, it has been used in
some studies to consolidate complete or partial remissions
achieved with chemotherapy. The gradual improvement in
results for patients with non-Hodgkin's lymphomas has
been very gratifying. This is particularly true for patients
with all stages of intermediate-grade lymphomas, the most
common type being diffuse large cell lymphoma.
The high-grade lymphomas, including the undifferentiated (Burkitt's and non-Burkitt's) lymphomas and lymphoblastic lymphomas, usually occur in children, and it is not
surprising that the greatest success has been seen in children. In our latest study, the 5-year survival of 36 patients
with Murphy stage I undifferentiated lymphomas who
were given combination chemotherapy was 100%. However, survival for children with leukemic manifestations
of both undifferentiated and lymphoblastic lymphomas
was poor.
The initial diagnosis ofnon-Hodgkin's lymphoma begins
with a suspicion that an enlarged lymph node or an extranodal mass may be malignant. In a child with lymphoblastic lymphoma or undifferentiated lymphoma, the
doubling time of the disease may be less than 24 hours.
Immediate biopsy is mandatory. Once the diagnosis is
established, the investigative procedures should be completed and treatment started within 24 hours. In older
patients with a diagnosis of a low-grade lymphoma, such
as an indolent follicular lymphoma, the time to biopsy
and pretreatment evaluation may be somewhat longer.

Follicular or Nodular Lymphomas
The clinical behavior of the follicular or nodular lymphomas is influenced by both the cell type and the stage,
though all are usually associated with an indolent course.
In the Working Formulation Classification, small cleaved
(formerly known as poorly differentiated lymphocytic) and
mixed cell types are called low-grade lymphomas, whereas
the large cell lymphomas are considered to be more aggressive and therefore are included among the intermediategrade lymphomas. Many of the clinical features of these
lymphomas are paradoxical. The follicular lymphomas are
seldom diagnosed in an early stage, yet even when diagnosed in an advanced stage they tend to run a chronic
course. Also, although advanced disease usually responds
to a variety of treatments, relapses are almost inevitable.
Because of these paradoxes, investigators disagree about
initial therapy, its timing, the importance of remission,
and the possibilities for cure. Regardless of these controversies, median survival rates ranging from 5 to 9 years for
patients with nodular lymphomas have been reported.
After sequential staging procedures that include lymphangiography, computed tomography, and bone marrow
biopsy, approximately 50% of patients have documented
evidence of stage IV disease, and 33% have stage III disease. In a research setting, where staging laparotomy is performed for patients with clinical stage I or II upper-torso
disease, approximately 60% have positive abdominal findings and thus have stage III disease.
Stages I and II
In general, patients with clinical or laparotomy-determined stage I or II disease live longer than those with more
advanced disease. Recently, several large patient series have
demonstrated that a fraction of patients with stage I or II
follicular lymphomas may be curable after radiotherapy
alone or radiotherapy in combination with chemotherapy.
In a study at Stanford University, patients who received
total lymphoid irradiation had a better freedom-fromrelapse rate than patients who received treat ment to
involved or extended fields. In our experience, patients
who received combination chemotherapy and radiotherapy
had a better 5-year relapse-free survival (RFS) rate (64%)
than those who received involved-field radiotherapy alone
(37%). Although laparotomy for staging can better define
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patients who would benefit from involved-field radiation
alone, future clinical research may demonstrate that more
extensive radiotherapy fields or adjuvant chemotherapy
regimens that control occult abdominal disease obviate
staging laparotomy.

Stage IV
Chemotherapy is the acknowledged standard treatment
for patients with stage IV follicula,r lymphomas. Little
information is available on treatment results for stage IV
disease because they are generally combined with those for
stage III. Although evidence is lacking that patients with
stage IV disease can be cured with current regimens, several studies have demonstrated a significant survival advantage for those who achieve remission. Most of the effective
combination chemotherapy regimens for low-grade lymphomas contain cyclophosphamide, vincristine, and prednisone. Doxorubicin, bleomycin, and procarbazine are
also common components of combination regimens.
Currently, our approach to treating stage IV disease is to
administer CHOP-Bleo chemotherapy to achieve a complete remission and subsequently, in an attempt to maintain this remission, administer the biologic response
modifier alpha-interferon.

Stage III
Although stages III and IV follicular lymphomas usually
respond to initial treatment with chemotherapy, long-term
studies have shown that patients with generalized disease
have a prolonged risk of relapse. Because relapse has been
assumed to be inevitable, the general conclusion has been
that patients with advanced stage III disease cannot be
cured. In 1981, Cox, who was then at the University of
Wisconsin, reported a 61 % RFS rate for 29 patients treated
with total lymphoid irradiation. The data suggested that
the RFS curve had reached a plateau, and thus that some
patients may have been cured. Subsequently, Paryani et al.
reported potential cures for approximately 40% of patients
with follicular small cleaved cell and follicular mixed lymphomas treated with radiotherapy.

Diffuse Large Cell Lymphomas
Diffuse large cell lymphomas (DLCLs), formerly known
as histiocytic lymphomas and before that as reticulum cell
sarcomas, are the most frequently occurring histologic
types of non-Hodgkin's lymphomas in adults.
Stages I and II
After sequential staging, short oflaparotomy, approximately 40% of all patients appear to have clinically localized. nodal or extranodal (E) presentations and no evidence
of generalized disease. Yet, before the advent of effective
combination chemotherapy, most patients who were given
involved-field radiotherapy for localized disease died of distant disease within 1 year. This was particularly true for
those with stage II or II-E disease-approximately 50% of
patients with localized presentations. Results for involvedfield radiotherapy have been satisfactory for only those few
patients with very limited extranodal stage I or I-E head
and neck disease (staged by the American Joint Committee
as Tl, T2, or TX) and for selected laparotomy-staged
patients with favorable localized disease presentations.
Thus, initial treatment for most patients with localized
presentations ofDLCL should be combination chemotherapy. Involved-field radiotherapy should be used to consolidate a good partial or complete remission.
Our treatment program has consisted of four cycles of
CHOP-Blea, alternated with involved-field radiotherapy,
for a maximum dose of 450 mg/m 2 of doxorubicin. Thereafter, treatment was completed with four cycles of COP
(cyclophosphamide, vincristine [Oncovin], and
prednisone) .
The 10-year survival rate for 147 patients treated on this
program was 65%. Multivariate analysis demonstrated that
survival was influenced adversely by age, gender, stage,

More recently, we reported our results for a combined
modality program ofCHOP-Bleo (cyclophosphamide,
doxorubicin [14-hydroxydaunomycin], vincristine
[Oncovin], prednisone, and bleomycin) chemotherapy and
radiotherapy for patients with stage III disease. This program resulted in a complete remission rate of 81 %, regardless of the disease's cell type, and the 5-year survival rate
was 75%. The corresponding RFS rate was 52% for all
patients and 64% for responders. Only one relapse occurred
4 years after treatment. A plateau in the RFS curve suggested many patients who achieved complete remission
were cured. Adverse prognostic factors for this treatment
approach included large cell histology, bulky abdominal
disease, and above-normal serum lactic dehydrogenase
(LDH) levels. The potential for cure mandates early intervention and treatment, when the disease is least extensive.

continued on page 6
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In addition, the original LSArL2 protocol has been
modified three times for the treatment oflymphoblastic
lymphoma and the related acute T cell lymphocytic leukemias. The effect of the latest regimen (T3A) proved to
be related to the status of the bone marrow. The 5-year
disease-free survival rate for patients with lymphoblastic
lymphoma who were not considered to hav<; leukemia was
100%, whereas the corresponding disease-free survival rate
for patients with acute T cell lymphocytic leukemia was
only 30%.
The status of the bone marrow also influenced the survival of patients with DSNCCL and other B cell lymphomas who were treated with high-dose cyclophosphamide
and high-dose methotrexate plus intrathecal methotrexate.
For 40 patients who were not considered to have leukemia,
the survival was 72%, whereas only one of seven patients
with leukemia survived over 5 years. Stage also influenced
the survival of patients with DSNCCL who did not have
leukemia. Five-year survival according to the Murphy staging system of36 patients with DSNCCL was 100% for
three patients with stage I disease, 71 % for eight patients
with stage II disease, and 72% for 21 patients with stage III
presentations. However, it was only 50% for four patients
with stage IV disease.
These results indicate that current treatment programs
are effective for lymphoblastic lymphoma and DSNCCL
stages I through IV but not for patients with evidenc~ of
associated leukemias. Other treatments are required for
leukemic presentations of both diseases.

tumor volume, and above-normal LDH levels. All 24
patients with no adverse factors or, at most, one adverse
factor survived up to 5 years, whereas the 5-year survival
rate for those with four or more risk factors was 37%.
Newer approaches to treatment are needed for patients in
the latter category-approximately 25% of patients with
localized presentations.

Stages ill and IV
Five-year survival rates of patients with stage III and stage
IV DLCL given various chemotherapy combinations have
ranged between 30% and 50%. Factors that reportedly
influence survival rates adversely include high tumor burden, above-normal LDH levels, and poor performance status. Stage of disease was less significant. We have identified
three prognostic groups of patients treated with CHOP-Bleo
(stage IV) or CHOP-Bleo and radiation (stage III). Those
with the best prognosis had a low tumor burden and a normal serum LDH level. Their complete remission rate was
96%, and their 5-year survival rate was 87%. Patients with a
poor prognosis had high tumor burdens and above-normal
serum LD H levels. Their complete remission rate was only
49%, and their 5-year survival rate was 20%. Patients with
an intermediate prognosis had either high tumor burdens
or an above-normal LDH level; their complete remission
rate was 71 %, and the corresponding survival rate was 48%.
These findings indicate that new treatment approaches are
needed for high-risk patients whose chances for a good
response to treatment and for survival are poor.

Lymphoblastic and Burkitt's or
Non-Burkitt's Lymphomas
Lymphoblastic lymphomas and Burkitt's and nonBurkitt's lymphomas, also known as undifferentiated
lymphomas or diffuse small noncleaved cell lymphomas
(DSNCCLs) in the Working Formulation Classification,
occur mostly in children. A breakthrough in the treatment
for children with these diseases occurred at the Memorial
Sloan-Kettering Cancer Center in New York in 1974.
Because of the strong tendency for both lymphoblastic
lymphoma and DSNCCL to involve the central nervous
system, Memorial Sloan-Kettering physicians empha--------sized-both---intrathecal---and-systemic-chemotherapy:-'fhe ·
LSArL2 (second lymphosarcoma, second leukemia) regimen consisted ofl0 chemotherapeutic agents (vincristine,
prednisone, cyclophosphamide, doxorubicin, methotrexate, cytosine arabinoside, bis-nitrosourea, L-asparaginase, thioguanine, and hydroxyurea) and radiotherapy to
the initial sites of disease. Subsequently, we found that
the LSAr L 2 regimen was more effective for children
with lymphoblastic lymphoma than for children with
DSNCCL. Our current protocol for DSNCCL consists
of high-dose cyclophosphamide and high-dose methotrexate with coordinated intrathecal methotrexate.

New Horizons in Understanding and Treating
Non-Hodgkin's Lymphomas
As a result of somatic mutation, genetically unstable
tumor cells may rapidly develop resistance. This genetic
instability may be a major limitation of cancer chemotherapy for any malignant disease. This hypothesis suggests
that the highest probability for such a mutation occurs in
tumors such as DSNCCL and lymphoblastic lymphomas
that have high numbers of malignant cells. The theory
implies that the best possibility for preventing the development of resistant cell lines is to treat the disease with as
many effective agents as possible using the highest permissibk---tlosage-s within-the--shmtesrtoterabl-e-rime--p-eriud~---------j
further expansion of this concept is to give consolidation
therapy after complete remission or good partial remissions
in high-risk patients. In this regard, intensive non-crossresistant regimens or very high-dose chemotherapy followed by autologous or allogeneic bone marrow transplantation may be effective. The roles of radiotherapy and bone
marrow transplantation remain to be defined.
The role of biologic response modifiers in the treatment
oflymphomas also needs to be defined. The initial enthusiasm for using bacillus Calmette-Guerin (BCG) or levamisole with combination chemotherapy was not sustained
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Early Discharge continued from page 3

because of equivocal findings. Currently, anti-idiotype
antibodies designed to take advantage of the presence of
certain antigens have not advanced beyond the experimental stage. Moreover, t he antibody technique has
been applied successfully only in patients with low-grade
lymphomas. New agents, which include interferon,
tumor necrosis factor, and interleukin-2, are currently
under investigation.
Recent molecular biology discoveries and the finding of
specific genetic changes in lymphoma (myc translocation in
Burkitt's lymphoma) have stimulated the search for similar
characteristics in other types oflymphoma. It is conceivable that unraveling the molecular basis for the neoplastic
lymphocytic transformation could lead to new diagnostic
and treatment concepts for all the lymphomas. ■

approximately $ll0 million nationwide. But Edwards is
quick to add that hospitals that typically perform fewer
mastectomies than does M. D. Anderson may not have the
support services necessary to prepare patients for early discharge. "The last thing I want to do," Edwards said, "is
admonish the community hospital to discharge patients
early when it may not have the resources for outpatient
management. To impose this kind of policy without regard
to the institution's capability of carrying it out would be
unwise."
Edwards' hesitancy in this regard is precisely why he
encourages increased physician involvement in cost-containment studies. The quality of patient care will not be
maintained if blanket policies are instituted by parties
that are unaware of the specific impact. What is needed,
Edwards said, is a critical examination of these issues by
those who are ultimately responsible for patient care:
physicians and surgeons.

Physicians who desire additional information may consult Hodgkin 1s
Disease and Non-Hodgkin 1s Lymphoma in Adults and Children (Raven Press,
1988), or write Lillian M. Fuller, M .D ., Department of Clinical Radiotherapy, Box 97, The University ofTexas M. D. Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, Texas 77030, or call (713) 792-3434.
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"Health care now occupies 10. 7% of the gross national
product," Edwards said (see illustration). "Whether that's
too much or too little I won't argue, but it's perceived by
~ - -~ome-as-heing----too-mucb___We_haY-e-to_minimize_cosLw_hi1"'-"-e- - maintaining quality. We physicians have to know the
amount of money saved and balance that against the potential for any increase in patient morbidity as we try to define
what is both cost effective and safe. In the past we admitted patients and no one worried about the cost, and consequently the cost of health care rose. I don't think any of us
want that anymore." ■
Physicians who desire additional information may write Charles M.
Balch, M .D ., Division of Surgery, Box 112, The University ofTexas
M . D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston,
Texas 77030, or call (713) 792-6446.
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Treatment Options continued from page 2
enhancing chemoth rap utic effecti en . Th procedure
is performed b sel cti l cannulating th rt rial upply
to the hepatic tumo r and t h n infu ing parti ulate material until stagnation of blood flo i achi
d. t M. D.
Anderson this therap has b en u d xt n iv l t treat
hepatocellular carcinoma, pr ducing an bj ti tumor
response in 40-50% of patient and impr ing ur i al. We
are currently in e tigating eff◄ cti en
fF DR ch moembolization for tr at ing color ctal li r m ta ta e .
Though colorectal liver m ta ta are a fr qu nt and
lethal complication of cancer com pl t r
ti n of th
metastases can provide a 25-35% 5- ear ur i al. To achieve
these results, an extensive preoperati
aluation mu t be
performed to properly select pat ients ho can potentiall
benefit from the procedure. Unfortunatel onl 10-15%
of patients with liver metastases are eligible for resectional
therapy. The remaining patients should be considered
for treatment with intra-arterial chemotherap or
chemoembolization. ■

another study is examining the impact of pulse intraarterial chemotherapy (administration of the daily FUDR
dose over a 6-hour period). Pulse therapy may reduce the
incidence and severity ofhepatobiliary toxicity and potentially enable prolongation ofintra-arterial therapy. Our goal
is to define the drug, dosage, and schedule of administration that most effectively improve survival.

Chemoembolization
Chemoembolization is primarily palliative to control
symptoms (e.g., pain or hemorrhaging) in patients who
have predominant liver metastases and extrahepatic disease
or have not responded to intra-arterial therapy. This therapy occludes the hepatic artery and thus depresses tumor
blood flow by 90%, significantly reducing the size of the
tumor. Hepatic neoplasms are devascularized by either
ligation at surgery or percutaneous embolization with particulate material such as polyvinyl alcohol foam (Ivalon) or
gelfoam. Arterial occlusion can be more effective when the
embolic material is mixed with chemotherapeutic agents
before administration. In addition to the direct effect of
ischemia, the emboli slow the drug transit time through
the vascular bed and increase drug-tumor contact time,

Physicians who desire addit ional information may \: rite Mark S. Roh ,
Box 106 The ni ersit ofTexas
M . D . Anderson Cancer Center 1515 Holcombe Boule ard Houston,
Texas 77030, or call (7 13) 792-7961.
M .D. , Department of General Surger
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